36276-24-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-4-methyl benzaldehyde is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new medicinal compounds. Its unique structure allows for the creation of drugs with specific therapeutic properties.
Used in Dye Industry:
In the dye industry, 3-Bromo-4-methyl benzaldehyde is used as a building block for the production of dyes, where its chemical properties contribute to the color and stability of the final product.
Used in Perfume Industry:
3-Bromo-4-methyl benzaldehyde is utilized as a component in perfumes due to its strong, sweet odor, enhancing the fragrance profile of various scent compositions.
Used in Chemical Research and Development:
3-Bromo-4-methyl benzaldehyde is employed as a reagent in organic synthesis reactions, facilitating the development of new chemical entities and contributing to the advancement of chemical research and innovation.

InChI:InChI=1/C8H7BrO/c1-6-2-3-7(5-10)4-8(6)9/h2-5H,1H3

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 501420-55-9 3-bromo-N-methoxy-N,4-dimethylbenzamide 
• 7726-95-6 bromine 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 68120-35-4 (3-bromo-4-methyl-phenyl)-methanol 

Downstream Products

• 95249-73-3 C₁₅H₁₂⁽²⁾H₃BrO 
• 362052-26-4 3-furan-2-yl-4-methyl-benzaldehyde 
• 675824-20-1 1-bromo-2-methyl-5-(4,4-dimethyl-2,6-dioxan-1-yl)benzene 
• 927670-52-8 4-(3-bromo-4-methyl-phenyl)-2-butyl-5-oxo-4,5,6,8-tetrahydro-1H-pyrano[3,4-b]pyridine-3-carboxylic acid ethyl ester 
• 675824-21-2 2-methyl-5-(4,4-dimethyl-2,6-dioxan-1-yl)benzaldehyde 
• 362052-29-7 (3-furan-2-yl-4-methyl-benzyl)-(3-phenoxy-phenyl)-amine 
• 95249-78-8 C₁₈H₁₇⁽²⁾H₃O 
• 95249-74-4 C₂₁H₁₆⁽²⁾H₃BrS 
• 95249-76-6 C₁₈H₁₆⁽²⁾H₃BrO 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The invention provides compounds of formula I: and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers, Alzheimer's disease, and conditions associated with demyelination.

Controlled Reduction of Tertiary Amides to the Corresponding Alcohols, Aldehydes, or Amines Using Dialkylboranes and Aminoborohydride Reagents

Dialkylboranes and aminoborohydrides are mild, selective reducing agents complementary to the commonly utilized amide reducing agents, such as lithium aluminum hydride (LiAlH4) and diisobutylaluminum hydride (DIBAL) reagents. Tertiary amides were reduced using 1 or 2 equiv of various dialkylboranes. The reduction of tertiary amides required 2 equiv of 9-borabicyclo[3.3.1]nonane (9-BBN) for complete reduction to give the corresponding tertiary amines. One equivalent of sterically hindered disiamylborane reacts with tertiary amides to afford the corresponding aldehydes. Aminoborohydrides are powerful and selective reducing agents for the reduction of tertiary amides. Lithium dimethylaminoborohydride and lithium diisopropylaminoborohydride are prepared from n-butyllithium and the corresponding amine-borane. Chloromagnesium dimethylaminoborohydride (ClMg+[H3B-NMe2]-, MgAB) is prepared by the reaction of dimethylamine-borane with methylmagnesium chloride. Solutions of aminoborohydride reduce aliphatic, aromatic, and heteroaromatic tertiary amides to give the corresponding alcohol, amine, or aldehyde depending on the steric requirement of the tertiary amide and the aminoborohydride used.

Reduction of Weinreb amides to aldehydes under ambient conditions with magnesium borohydride reagents Dedicated to the memory of Professor Sheldon Shore

Chloromagnesium dimethylaminoborohydride (ClMg+ [H3BNMe2]-, MgAB) is an analogue of the versatile lithium dialkylaminoborohydrides (LAB reagents), prepared by the reaction of dimethylamine-borane with methylmagnesium chloride. MgAB is a partial reducing agent for Weinreb amides under ambient conditions and is complementary to the commonly utilized lithium aluminum hydride (LiAlH4) and diisobutylaluminum hydride (DIBAL) reagents, while exhibiting enhanced chemoselectivity. To prevent over-reduction, the aldehyde products are readily isolated in good yields by forming the sodium bisulfite adducts. Aldehyde products can both be stored and later used as the bisulfite adducts, or can be regenerated from the bisulfite adducts by treatment with aqueous formaldehyde.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

THERAPEUTIC COMPOUNDS

The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.

Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: Novel analogues of 4-[1-(3,5,5,8,8- Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,

Three unreported analogues of 4-[1-(3,5,5,8,8-pentamethyl-5-6-7-8- tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), otherwise known as bexarotene, as well as four novel analogues of (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6- pentamethylnaphthalen-7-yl)-4-hydr

Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase

The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.

Metallation effects on the thermal interconversion of atropisomers of di(orthomethylarene)-substituted porphyrins

A new series of meso-substituted diaryl free-base and metalloporphyrins have been prepared. Each arene has been substituted with both a methyl group in the ortho position and a formyl group in the meta position. Rotation of the arene units is prevented at

Triaromatic vitamin D analogues

The invention relates, as novel and useful industrial products, to triaromatic compounds, which are vitamin D analogues, of general formula (I): and also to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.